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Non-steroidal anti-inflammatory drugs (NSAIDs) are regarded as the cornerstone of con-
ventional treatment for AS. However little is known about concomitant NSAID use during
treatment (with TNF-α inhibitors) in daily clinical practice.
Methods and findings
Consecutive patients from the GLAS cohort were included. NSAID use and ASAS-NSAID
index were evaluated at group level and at individual patient level during 52 weeks of fol-
low-up. Analyses were stratified for treatment regimen. Generalized estimating equations
(GEE) was used to evaluate NSAID use in relation to assessments of disease activity
over time. In patients starting TNF-α inhibitors (n = 254), 79% used NSAIDs at baseline
and this proportion decreased significantly to 38% at 52 weeks. ASAS-NSAID index also
decreased significantly from median 65 to 0. In patients on conventional treatment (n =
139), 74% used NSAIDs at baseline with median ASAS-NSAID index of 50 and this
remained stable during follow-up. At each follow-up visit, approximately half of the
patients changed their type or dose of NSAIDs. GEE analysis over time showed that
NSAID use was associated with AS disease activity score (p<0.05). This relation was
more pronounced in patients treated with TNF-α inhibitors compared to conventional
treatment (B = 0.825 vs. B = 0.250).
Conclusions
In this observational cohort of established AS patients, there was no difference in baseline
NSAID use between patients with and without indication for TNF-α inhibitors. NSAID use
decreased significantly after starting TNF-α inhibitors. During conventional treatment,
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NSAID use remained stable at group level. However, NSAID use changed frequently at indi-
vidual patient level and was significantly associated with disease activity.
Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that primarily affects
the axial skeleton. Non-steroidal anti-inflammatory drugs (NSAIDs) are regarded as the cor-
nerstone of conventional treatment for AS.[1] NSAIDs have shown good reduction of symp-
toms in 60–80% of the patients.[2] A recent network meta-analysis of randomized controlled
trials (RCTs), reporting on the efficacy of different NSAIDs in AS, showed that the majority of
available NSAIDs reduce total pain score significantly compared to placebo up to 12 weeks.[3]
Besides the positive effect on pain, NSAIDs also reduce the level of acute-phase reactants in the
blood of AS patients.[4] Furthermore, a decrease in signal intensity of bone marrow edema of
the sacroiliac (SI) joints on MRI was seen after 6 weeks of full dose NSAIDs in newly diag-
nosed patients with axial spondyloarthritis (SpA).[5] During treatment, disadvantages of
NSAIDs such as possible cardiovascular and gastrointestinal side effects should be taken into
account, especially in patients with comorbidity and comedication (e.g. anticoagulants).[6,7]
In AS, there is only limited data available comparing the efficacy of continued use of
NSAIDs with on demand use. A single RCT studied symptom control and safety of continued
versus on demand use of celecoxib and ketoprofen during 2 years of follow-up as a secondary
outcome. No differences were found between the groups.[7] A recent Cochrane review on
both traditional and COX-2 selective NSAIDs in AS found no difference in harms between
NSAIDs and placebo during 12 weeks of follow-up.[8] Conflicting results were published
about the effect of continued versus on demand use of NSAIDs on spinal radiographic pro-
gression in AS.[9,10]
For over a decade, tumor necrosis factor-alpha (TNF-α) inhibitors are available for AS
patients with active disease who have insufficient response to conventional treatment includ-
ing NSAIDs. TNF-α inhibitors have shown to reduce the clinical signs and symptoms as well
as serum levels of CRP and axial inflammation detected on MRI in AS patients with active dis-
ease.[11] A head to head comparison between NSAIDs and TNF-α inhibitors on efficacy in
treatment naïve patients has never been performed. Additionally, little is known about the
additional efficacy of concomitant NSAID use to the treatment of biologicals in AS. Therefore,
it can be questioned whether AS patients should be advised to stop or continue their NSAIDs
during TNF-α inhibitor use.[5]
So far, studies on concomitant NSAID use to the treatment of biologicals were only per-
formed in patients with early active axiale SpA.[12–15] A recent RCT showed that patients
reached partial remission more frequently during treatment with infliximab combined with
naproxen than during naproxen treatment alone.[16] Another recent RCT showed the NSAID
sparing effect of etanercept treatment. Patients were able to reduce their NSAID intake by
more than half during 8 weeks of etanercept treatment.[15] In the observational DESIR cohort,
patients were included presenting with inflammatory back pain, symptom duration between
3 months and 3 years and symptoms suggestive of spondyloarthritis according to the local
investigator. However, these patients did not necessarily fulfill the modified New York criteria
for AS.[13] Patients receiving TNF-α inhibitors from this cohort were matched to patients on
conventional treatment using propensity scores. After 2 years of follow-up, in both treatment
groups the proportion of patients using NSAIDs decreased as well as the Assessment of Spon-
dyloarthritis international Society (ASAS)-NSAID index, which is based on the specific
ASDAS is related to NSAID use
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NSAID, dosage and frequency. These results were significantly more pronounced in the group
receiving TNF-α inhibitors.[15] Based on these results, it was concluded that most patients
can reduce their intake of NSAIDs after starting TNF-α inhibitors. However, not all patients
receiving TNF-α inhibitors were able to stop or decrease their NSAID intake.
The aim of the present study was to evaluate NSAID use over time and to investigate if
NSAID use was related to disease activity in patients with established AS from a large observa-
tional cohort study starting TNF-α inhibitors or receiving conventional treatment during a fol-
low-up period of 52 weeks.
Methods
Patients
The GLAS cohort was approved by the local ethics committees of the MCL and UMCG and all
patients provided written informed consent according to the Declaration of Helsinki. The
present analysis was performed in the Groningen Leeuwarden Ankylosing Spondylitis (GLAS)
cohort. The GLAS cohort is an ongoing prospective longitudinal observational cohort study
with standardized follow-up. Since November 2004, consecutive AS outpatients who started
TNF-α inhibitors from the University Medical Center Groningen (UMCG) and the Medical
Center Leeuwarden (MCL) were included.[17] In 2009, this inclusion was extended to all con-
secutive axial SpA outpatients, irrespective of treatment regimen. All patients were 18 years or
older and fulfilled the modified New York criteria for AS (>90%) or the ASAS criteria for axial
SpA including MRI. All patients included before June 2013 were included in this analysis.
Patients were excluded if they started TNF-α inhibitors prior to inclusion in the GLAS cohort
or had an indication but did not start with TNF-α inhibitors due to non-medical reasons, such
as the patient’s own preference (Fig 1).
Treatment
NSAIDs were prescribed based on expert opinion. TNF-α inhibitors were started according to
the ASAS consensus statement.[18] The choice between available TNF-α inhibitors was based
on the judgment of the treating rheumatologist and/or the specific preference of the patient.
[17] After 3 months of TNF-α inhibitor treatment, patients with low disease activity were
advised to take NSAIDs on demand. There was no difference in treatment advice between
males and females.
Follow-up and clinical assessments
Visits were scheduled at baseline (before start of TNF-α inhibitors) and after 6, 12, 24 and 52
weeks for the TNF-α inhibitor group. The conventional treatment group had scheduled visits
at baseline, 24 and 52 weeks. At every visit, disease activity was assessed using the AS Disease
Activity Score (ASDAS), Bath AS Disease Activity Index (BASDAI), and serum CRP level.
[19–20]
At every visit, NSAID use (yes/no) and type of NSAID was recorded. Dosage and frequency
were assessed retrospectively from clinical records to calculate the ASAS-NSAID index. This
index takes the specific NSAID and dosage into account as well as the percentage of days of
NSAID intake during a period of interest.[1,21] A score of 100 is equal to a full dose of NSAIDs
all days of the week. For situations in which the exact amount of NSAID use was unclear, a fre-
quency of 2 days a week was used for occasional NSAID use (1 to 3 days a week) and 0.5 days a
week for very rare NSAID use (<1 day a week). To determine the changes in NSAID use, the
ASDAS is related to NSAID use
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type and dosage of NSAIDs was assessed at each visit to investigate starting, switching, dose
escalation, dose reduction or complete stop of NSAIDs.
Statistics
Results were expressed as number of patients (%) and mean ± SD or median (interquartile
range; IQR), for categorical and normally or non-normally distributed data, respectively. Anal-
yses were stratified for treatment regimen: patients starting TNF-α inhibitors and patients on
conventional treatment. Chi-square or Fisher’s Exact tests, Independent Samples t-tests, and
Mann-Whitney U-tests were used to compare baseline characteristics. Linear and logistic gen-
eralized estimating equations (GEE) were used to analyze NSAID use over time. GEE is a tech-
nique for longitudinal data analysis, which makes use of all available data and allows unequal
numbers of repeated measurements.[22] The ‘exchangeable’ correlation structure was used to
correct for within patient correlation. If there was no normal distribution of residuals, parame-
ters were log-transformed before being entered into the equation.
GEE was also applied to analyze the relation between NSAID use and disease activity over
time, where disease activity was defined as the dependent variable. NSAID use was analyzed
using 4 parameters: NSAID use (yes versus no), ASAS-NSAID index (continuous scale), low
(index10 versus <10), and high use (index90 versus <90). To exclude potential bias due
to TNF-α inhibitors discontinuation, analyses were also performed in patients using TNF-α
inhibitors80% of the follow up time. To exclude the influence of the initial positive effect of
TNF-α inhibitors on the association between NSAID use and disease activity, analyses were
Fig 1. Flowchart of inclusion.
https://doi.org/10.1371/journal.pone.0196281.g001
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also performed for 12 to 52 weeks of follow-up. P-values<0.05 were considered statistically
significant. Statistical analysis was performed with IBM SPSS Statistics 22 (SPSS, Chicago, IL,
USA).
Results
Of the 393 included AS patients, 67% were male, mean age was 44 ± 13 years, median symp-
tom duration 15 years (IQR 8–24), and 79% were HLA-B27 positive. Additionally, 254 (66%)
patients started TNF-α inhibitors due to active disease (etanercept (58%), adalimumab (26%),
or infliximab (15%)). Of the 254 patients who started TNF-α inhibitors, 217 (85%) used this
treatment more than 80% of the follow-up time. The remaining 139 (34%) patients received
conventional treatment. Patient characteristics were comparable between both groups, except
higher disease activity, more often peripheral arthritis, and worse physical functioning in
patients starting TNF-α inhibitors.(Table 1)
NSAID use at group level
At baseline, 77% of patients used 12 different NSAIDs, mostly diclofenac (16%), naproxen
(16%) and piroxicam (7%).(S1 Table) Baseline NSAID use was comparable between patients
who started TNF-α inhibitors and patients on conventional treatment (79% vs. 74%). In
patients who started TNF-α inhibitors, this proportion decreased significantly during follow-
Table 1. Baseline characteristics of the AS study population.
Total TNF-α inhibitors Conventional treatment P-value
n = 393 n = 254 n = 139
Patient characteristics
Age (yrs) 44 ± 13 43 ± 12 44 ± 14 0.451
Male gender 261 (66%) 173 (68%) 88 (64%) 0.253
HLA-B27+ 294 (79%) 197 (81%) 97 (75%) 0.094
Duration of symptoms (yrs) 15 (8–24) 15 (9–24) 14 (7–24) 0.393
Time since diagnosis (yrs) 6 (1–16) 7 (1–24) 5 (1–16) 0.693
History of extra-spinal manifestations
Peripheral arthritis 102 (27%) 76 (31%) 26 (20%) 0.015
IBD 36 (10%) 23 (9%) 13 (10%) 0.495
Uveitis 108 (28%) 73 (29%) 35 (27%) 0.334
Psoriasis 28 (7%) 15 (6%) 13 (10%) 0.125
Disease status
BASDAI (range 0 to 10) 5.3 ± 2.2 6.1 ± 1.7 3.9 ± 2.2 <0.001
ASDAS 3.3 ± 1.1 3.8 ± 0.8 2.4 ± 0.9 <0.001
CRP (mg/l) 8 (8–17) 13 (5–22) 3 (2–7) <0.001
ESR (mm/h) 14 (7–28) 21 (10–35) 9 (4–13) <0.001
Peripheral arthritis 50 (13%) 43 (17%) 7 (5%) <0.001
BASFI (range 0 to 10) 4.8 ± 2.5 5.7 ± 2.1 3.2 ± 2.3 <0.001
Concomitant medication use
Current NSAID use 289 (77%) 194 (79%) 95 (74%) 0.131
Current DMARD use 57 (15%) 47 (19%) 10 (7%) 0.002
p-value: TNF-α inhibitors vs. conventional treatment. Values are number of patients (percentage), mean ± SD or median (IQR). HLA-B27+, human leukocyte antigen
B27 positive; IBD, inflammatory bowel disease; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ASDAS, Ankylosing Spondylitis Disease Activity Score;
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; BASFI, Bath Ankylosing Spondylitis Functional Index; DMARD, disease-modifying antirheumatic drug
https://doi.org/10.1371/journal.pone.0196281.t001
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up to 38% at 52 weeks. When analyzing 2 different subgroups, low on demand and high
NSAID use (defined by ASAS-NSAID as index resp. <10 and90), the largest decrease in
NSAID use was found during the first 6 weeks, followed by a slower gradual decrease up to 52
weeks.(Table 2) In the conventional treatment group, the proportion of patients using NSAIDs
remained stable over time (82% at 52 weeks).(Table 2)
Patients starting TNF-α inhibitors also showed a rapid and significant decrease in ASAS-NSAID
index during the first 6 to 12 weeks and this reduction remained stable during all follow-up visits.
In patients on conventional treatment, the total ASAS-NSAID index and subgroups did not change
over time.(Table 2) These patterns were found in both males and females (data not shown). GEE
analysis showed no significant interaction between gender and ASAS-NSAID index over time.
In total, 22 patients (6%) never used NSAIDs, of which 18 patients in the TNF-α inhibitor
group and 4 patients in the conventional treatment group. In the TNF-α inhibitor group, 9
patients had known contraindications for NSAID use (gastrointestinal (n = 4), renal (n = 4)
and a proven allergy (n = 1)). In the conventional treatment group, there were no known
contraindications.
NSAID use at individual patient level
Assessing the variability in NSAID use at individual patient level revealed that 46 to 67% of the
patients treated with TNF-α inhibitors remained on a stable dose at each follow-up visit. Fur-
thermore, 20 to 46% of the patients reduced their dose or stopped NSAIDs at a follow-up visit.
Additionally, only 8 to 15% of the patients increased their dose, started or switched NSAIDs at
a follow-up visit.(Table 3) Of the patients using NSAIDs at baseline, 48% had stopped their
NSAIDs 52 weeks after starting TNF-α inhibitors.
Although NSAID use at group level was stable over time in the conventional treatment
group, there were many changes at individual patient level. At each follow-up visit, approxi-
mately half of the patients changed their NSAID use: 26 to 34% of the patients showed dose
escalation, start or switch of NSAIDs and 21 to 26% dose reduction or stop of NSAIDs.
(Table 3) Only 7% used NSAIDs at baseline and not at 52 weeks, where 13% did not use
NSAIDs at baseline but had started at 52 weeks of follow up.
NSAID use in relation to disease activity
Disease activity reduced significantly after starting TNF-α inhibitors and remained low and
stable during follow-up. In the conventional treatment group, disease activity was low and
Table 2. Changes in NSAID use at group level.
Baseline 6 weeks 12 weeks 24 weeks 52 weeks p- value
TNF-α inhibitors n = 245 n = 214 n = 223 n = 223 n = 217
NSAID use (Y/N) 79% 57% 47% 41% 38% <0.001
ASAS-NSAID index 65 (23–100) 25 (0–60) 0 (0–50) 0 (0–50) 0 (0–50) <0.001
NSAID use low 24% 47% 56% 76% 77% <0.001
NSAID use high 44% 21% 15% 16% 14% <0.001
Conventional treatment n = 129 n = 109 n = 112
NSAID use (Y/N) 74% 80% 82% 0.183
ASAS-NSAID index 50 (0–100) 50 (5–100) 50 (7–100) 0.382
NSAID use low 44% 31% 28% 0.448
NSAID use high 36% 37% 38% 0.721
Values are percentage of patients or median (IQR).
https://doi.org/10.1371/journal.pone.0196281.t002
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stable at all visits.(Fig 2) At 52 weeks, disease activity was comparable between both groups,
BASDAI mean 3.4 vs. 3.7, ASDAS mean 2.2 vs. 2.3, and CRP median 3 vs. 3 respectively.
GEE analysis over time showed that NSAID use was significantly associated with disease
activity. In the TNF-α inhibitor group, a significant association of all 4 NSAID parameters
(NSAID use (yes/no), ASAS-NSAID index, low on demand use and high use) with ASDAS
was found. GEE revealed that higher NSAID use was related to higher ASDAS and vice versa.
(Table 4) Comparable results were found for BASDAI and CRP.(S2 and S3 Tables)
The association between NSAID use and ASDAS remained significant in patients who used
TNF-α inhibitors more than 80% of the follow-up time and when analyzing only 12 to 52
weeks of follow-up to exclude the initial effect of TNF-α inhibitors, although the regression
coefficients were lower in these last analyses. (S4 Table)
In the conventional treatment group, a significant but less prominent association of 3
NSAID parameters NSAID use (yes/no), low on demand use and high use) with ASDAS was
found. (Table 4) BASDAI was only significantly associated with low on demand NSAID use.
For CRP, no significant associations with NSAID use were found.
Discussion
In the present prospective observational cohort study, we evaluated NSAID use in relation to
disease activity during 52 weeks of follow-up in established AS patients treated with and with-
out TNF-α inhibitors in daily clinical practice. This is the first study assessing the difference in
NSAID use at group level and at individual patient level in established AS.
In the TNF-α inhibitor group, a rapid and significant decrease of concomitant NSAID use
was seen. NSAID use at group level remained low during the entire follow-up period.
Although patients in our cohort were advised to take their NSAID on demand after 3 months
of TNF-α inhibitor treatment, many patients reduced or stopped NSAIDs on their own initia-
tive even earlier. The reason for this is most likely the positive effect on symptoms of TNF-α
inhibitors. Our finding of rapid NSAID reduction after 6–12 weeks of TNF-α inhibitor treat-
ment is in line with a previous RCT in early axial SpA which showed the NSAID sparing effect
of 8 weeks etanercept treatment.[15] Additionally, early axial SpA patients of the DESIR cohort
showed a gradual decline in NSAID use after starting TNF-α inhibitors during 2 years of fol-
low-up.[14]
In our conventional treatment group, NSAID use remained stable over 52 weeks of follow-
up, whereas in the conventional care group of the DESIR cohort a significant decrease in
Table 3. Changes in NSAID use at individual patient level.
Baseline 6 weeks 12 weeks 24 weeks 52 weeks
TNF-α Inhibitors
NSAID use at baseline 79%
Dose escalation, start or switch 8% 11% 13% 15%
Stable dose 46% 59% 67% 61%
Dose reduction or stop 46% 30% 20% 24%
Conventional treatment
NSAID use at baseline 74%
Dose escalation, start or switch 34% 26%
Stable dose 46% 49%
Dose reduction or stop 21% 26%
Patients who used no NSAIDs during follow-up were excluded from this table: 11% in TNF-α Inhibitor group and 6% in the conventional treatment group.
https://doi.org/10.1371/journal.pone.0196281.t003
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NSAID use over 2 years was shown.[14] The GLAS cohort is an established AS cohort in con-
trast to the DESIR cohort, which includes patients with recent-onset (<3 years) inflammatory
back pain suggestive of axial SpA.[14] Furthermore, DESIR used propensity scores to match
the conventional treatment group to the TNF-α inhibitor group. This may explain the differ-
ences in the course of NSAID use between the conventional treatment groups of both cohorts.
In concordance with our results, in the DESIR cohort the decrease in NSAID use of patients
Fig 2. Disease activity over time in AS patients. ASDAS over time in patients starting TNF-α inhibitors (A) and
receiving conventional treatment (B); BASDAI over time in patients starting TNF-α inhibitors (C) and receiving
conventional treatment (D); CRP over time in patients starting TNF-α inhibitors (E) and receiving conventional
treatment (F). p<0.05 compared to baseline. Box-and-whisker plots: boxes indicate medians with interquartile
ranges; + indicate means; whiskers indicate 5–95 percentile; • indicate outliers.
https://doi.org/10.1371/journal.pone.0196281.g002
ASDAS is related to NSAID use
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on conventional treatment was also less pronounced than in patients starting TNF-α inhibitor
group.[14]
In our GLAS cohort, frequent inter-individual changes in NSAID use were observed at
each follow-up visit in both treatment groups. Interestingly, GEE analysis over time showed
that NSAID use was significantly associated with disease activity. In the TNF-α inhibitor
group, this relation was most pronounced and significant for all disease activity measures (i.e.
ASDAS, BASDAI and CRP). Results remained significant when including patients who used
TNF-α inhibitors more than 80% of the follow-up time and when analyzing 12 to 52 weeks of
follow-up to exclude the influence of the initial positive effect of TNF-α inhibitors on the GEE
analyses.
In the conventional treatment group, the association between NSAID use and disease activ-
ity was less pronounced and only found for ASDAS. This can be explained by less variation in
disease activity in this treatment group, e.g. the large majority of patients had normal CRP lev-
els, but it can also be related to lower power in GEE analysis because of the lower number of
included patients and less frequent follow-up visits.
Since this is an observational cohort study in AS patients, it reflects NSAID use in daily clin-
ical practice. No sub-analyses were performed on specific NSAIDs, e.g. traditional and COX-2
NSAIDs, due to small numbers. However, a recent meta-analysis showed no clear superiority
in efficacy of any specific NSAID.[3] Unfortunately, systematic data on the side effects of
NSAIDs were missing in our study, which potentially could have explained why patients
reduced or stopped their NSAID intake. Despite this limitation, a positive association between
NSAID use and disease activity was still found.
In summary, this is the first study investigating NSAID use in an established AS cohort on
TNF-α inhibitors or conventional treatment. At baseline, we found no differences in NSAID
use between AS patients with and without indication for TNF-α inhibitors. After starting
TNF-α inhibitors, NSAID use decreased rapidly and remained low during follow-up. In
patients receiving conventional treatment, NSAID use remained stable at group level over
time. Conversely, at individual patient level, both the type and dose of NSAIDs changed fre-
quently irrespective of treatment regimen. Therefore, stable NSAID use at group level does not
necessarily reflect stable NSAID use at individual patient level. This should be taken into
account in future evaluations and research on NSAID use in axial SpA. Most importantly, this
is the first prospective cohort study of established AS patients that showed NSAID use was sig-
nificantly associated with assessments of disease activity, which was most pronounced for
patients treated with TNF-α inhibitors.
Table 4. Association between ASDAS and NSAID use over time in AS patients.
B (95% CI) P-value Interval n
TNF-α Inhibitors
NSAID use Yes 0.825 (0.664–0.985) <0.001 1074 251
ASAS-NSAID index 0.009 (0.007–0.012) <0.001 1073 251
NSAID use low -0.831 (-0.672- -0.990) <0.001 1073 251
NSAID use high 0.855 (0.682–1.028) <0.001 1073 251
Conventional treatment
NSAID use Yes 0.250 (0.006–0.493) 0.045 315 131
ASAS-NSAID index 0.002 (0.000–0.005) 0.059 314 131
NSAID use low - 0.223 (-0.425–0.022) 0.030 314 131
NSAID use high 0.269 (0.038–0.501) 0.023 314 131
https://doi.org/10.1371/journal.pone.0196281.t004
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